Johnson and Johnson gets CDSCO panel nod to study Paliperidone Palmitate

Pharmaceutical major, Johnson and Johnson has got a go ahead from the Subject Expert Committee SEC functional under Central Drug Standard Control Organization CDSCO to conduct Phase III clinical trial for antipsychotic Paliperidone Palmitate Prolonged Release Suspension for intramuscular injection 700 mg and 1000 mg, 6 months injection (PP6M) in India.

This came after the drug maker Johnson and Johnson represented comparative efficacy/safety data of PP6M Vs PP3M and PP6M vs PP1M of global clinical trial in global and ethnic Indian (or Indian Origin) patients.

For more details, check out the link given below:

JnJ Gets CDSCO Panel Nod To Study Antipsychotic Drug Paliperidone Palmitate